Last reviewed · How we verify
PACAP
At a glance
| Generic name | PACAP |
|---|---|
| Also known as | Pituitary adenylate cyclase-activating polypeptide |
| Sponsor | Danish Headache Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine (NA)
- Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 (NA)
- Platelet Rich Plasma Combined With Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis (NA)
- NDPH Biomarker Study in Children and Adolescents
- Changes in PACAP, CGRP, and VIP Levels in Rosacea Patients on Systemic Isotretinoin and Their Association with Erythema (PHASE4)
- Role of Specific microRNAs in Cluster Headache
- Comparison of the Effects of Single Versus Triple Injections of Platelet-Rich Plasma in Patients With Knee Osteoarthritis (NA)
- Repeat Dosing of Psilocybin in Migraine Headache (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PACAP CI brief — competitive landscape report
- PACAP updates RSS · CI watch RSS
- Danish Headache Center portfolio CI